Biotech RadarJobs updated

COMPANY

MedRegen

HQ: Baltimore, MD source · medregenco.com ↗

Clinical Phase 2

Location: Baltimore, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Wound of Skin Abdominal Wound Amyotrophic Lateral Sclerosis Lou Gehrig Disease Motor Neuron Disease Motor Neuron Atrophy Acute Respiratory Distress Syndrome Respiratory Failure Respiratory Distress Syndrome Respiratory Tract Diseases Cytokine Storm Alcoholic Hepatitis Acute Alcoholic Hepatitis COVID-19 Human ARDS Stem Cells Regeneration MRG-001 MRG-001 (Low-dose) MRG-001 (High-dose)

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: MRG-001 in Patients With Amyotrophic Lateral Sclerosis source ↗
  2. Trial start Phase 2: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients source ↗
  3. Trial start Phase 2: MRG-001 in Patients With Alcoholic Hepatitis source ↗
  4. Trial start Phase 2: Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients source ↗
  5. Trial start Phase 2: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients source ↗

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT05844527Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty PatientsPhase 2CompletedNov 20, 2023Sep 1, 2024 (actual)
NCT06315608MRG-001 in Patients With Amyotrophic Lateral SclerosisPhase 2Unknown status (ClinicalTrials.gov)Jul 1, 2025Jan 1, 2026 (estimated)
NCT06308926MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS PatientsPhase 2Unknown status (ClinicalTrials.gov)Dec 1, 2024Feb 1, 2026 (estimated)
NCT06307522MRG-001 in Patients With Alcoholic HepatitisPhase 2Not yet recruitingSep 1, 2024Sep 1, 2026 (estimated)
NCT04646603MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 PatientsPhase 2Unknown status (ClinicalTrials.gov)Dec 1, 2021Mar 31, 2022 (estimated)
Feedback